Empasiprubart

Empasiprubart 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为AChR-Ab Seropositive Generalized Myasthenia Gravis、Myasthenia Gravis、MG、gMG。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Empasiprubart 研究

• ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

  不适用招募中美国比利时德国GreeceNCT07294170

• ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis

  II 期招募中美国Greece西班牙NCT07673627

• ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

  II 期招募中美国比利时德国GreeceNCT07284420

• A Study to Assess the Effect of Empasiprubart on Nerve Morphology by Ultrasound in Adults With Multifocal Motor Neuropathy

  I 期招募中GeorgiaNCT07610564

• A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

  III 期招募中美国Argentina澳大利亚奥地利NCT06920004

• A Study to Assess the Absolute Bioavailability of Empasiprubart SC Administered With an Autoinjector and the Pharmacokinetic Noninferiority of Empasiprubart SC Versus Intravenous (IV) in Healthy Adult Participants

  I 期招募中加拿大NCT07612020

• A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

  III 期招募中美国Argentina奥地利BrazilNCT07091630

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。